Test a device to choose the first chemo for metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have confirmed colorectal adenocarcinoma that has spread (metastatic disease), with at least one measurable spot
- Your cancer doctor says you can use standard chemo plans like FOLFOX/FOLFIRI/FOLFIRINOX (with or without certain targeted medicines, depending on your tumor markers)
- You are able to have the Oncogramme® test done, and you’re generally well enough (WHO health status 0 to 2, expected survival over 3 months)
- Your blood and organ tests are within limits (enough white blood cells, platelets, hemoglobin; and acceptable liver, kidney, and electrolyte levels)
- You have not had prior chemotherapy before (except certain past peri-operative/adjuvant chemo that ended more than 6 months ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial uses a special PET scan called 18F-FDG to see how well your first chemotherapy is working, just a couple of weeks after you start. The goal is to find out early whether the treatment is helping, so you and your doctor can decide together if you should continue or switch to a different approach.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.